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Enhancing the Understanding of Pre-Type 1
Diabetes in the General Population
T
ype 1 diabetes occurs in 90% of
patientswithnofamilyhistoryofthe
disease. The majority of studies
seeking to identify at-risk subjects have
been conducted in ﬁrst-degree relatives
who comprise just 10% of all cases of
type 1 diabetes but may have a 20-fold
increased risk for type 1 diabetes (1).
Although the peak incidence occurs at
adolescence, there are data to suggest
that 5–10% of all adults diagnosed with
type2diabetesmayactuallyhavetype1
diabetes(latentautoimmunediabetesin
adults [LADA]). If type 1 diabetes is to
be prevented, signiﬁcantly enhanced
understanding of both the mechanisms
leading to type 1 diabetes and the nat-
ural history of the pre-diabetic period is
essential.
Current evidence suggests that type 1
diabetes results from a complex interac-
tion between type 1 diabetes genetic sus-
ceptibility (predominantly HLA Class II
associations) and environmental expo-
sure(s) leading to a breakdown of toler-
ance culminating in -cell autoimmunity
and destruction (2). In the process lead-
ing to overt type 1 diabetes, both T and B
lymphocytesareactivated.B-lymphocyte
activation is characterized by the emer-
gence of cytoplasmic islet cell auto-
antibodies (ICAs) and one or more
autoantibodies against the -cell–speciﬁc
autoantigen insulin, glutamate decarbox-
ylase, the IA-2 protein tyrosine phospha-
tase, or the zinc transporter ZnT8 (IAA,
GADA, IA-2A, and ZnT8A, respectively).
For the most part, IAA, GADA, IA-2A,
and ZnT8A have replaced ICA, which is
measured using indirect immunoﬂuores-
cencethatrequiresasubjectiveevaluation
of the ﬂuorescence intensity. The IAA,
GADA, IA-2A, and ZnT8A analyses re-
quire only small amounts of serum (5–20
linmostassays)andarethuswellsuited
forlarge-scalestudiescomprisingbothin-
fants and small children. Serum samples
can be safely stored at 20°C for years
before the measurement of the autoanti-
bodies is undertaken, and the samples
usually also tolerate repeated freeze-thaw
cycleswithoutalterationsinthemeasured
concentrations. Analyses of T-cell func-
tion—both regulatory (tolerance) and ef-
fector (-cell killing)—are highly
demanding and poorly reproducible be-
tween most laboratories. Most assays re-
quire large volumes of freshly drawn
blood, are labor-intensive, and have lim-
ited, if any, predictive ability on their
own. In general, when autoantibodies are
presentincombination,athighertiters,at
a younger age, and with high-risk HLA
genes, the predictability of the disease in
relatives is well over 50% in a 5-year pe-
riod (3,4).
Deﬁning individuals at risk for type 1
diabetes is crucial for both understanding
the etiopathogenesis of the disease as well
as instituting preventative strategies. Two
approachesexist1)primaryautoantibody
screening followed by quantiﬁcation of
riskbyfurtherautoantibody,genetic,and
metabolic testing, and 2) primary genetic
screening (e.g., of newborns using cord
blood or dried blood spots) with deter-
mination of high-risk HLA (DR/DQ)
gene alleles and subsequent quantiﬁca-
tion of risk by further autoantibody and
metabolic testing. Depending on the
circumstances, both approaches have
their advantages and disadvantages (5).
Thevalueofdiabetes-associatedauto-
antibodies in the prediction of clinical
type 1 diabetes has been ﬁrmly docu-
mentedintheﬁrst-degreerelativesoftype
1 diabetes probands of subjects affected
with the disease, as well as in subjects in
the general population who develop type
1diabetes.However,thetimeoflifewhen
thediseaseactuallybegins,andtheinduc-
tive events that trigger this process, have
remained elusive. The earlier German
BABYDIAB study, Finnish Diabetes Pre-
diction and Prevention (DIPP) study,
Denver Study of Diabetes in the Young
(DAISY) as well as the Florida-Georgia
Prospective Assessment of Newborns for
Diabetes Autoimmunity (PANDA) study
have screened newborns for genetic risk
and followed those with increased diabe-
tes susceptibility at frequent intervals
from birth onward in an attempt to iden-
tify potential environmental factors that
contribute to the development of autoim-
munity and subsequent diabetes. How-
ever, these studies were limited mostly by
insufﬁcient power resulting from the rel-
atively small numbers of patients fol-
lowed.Fiveyearsago,TheEnvironmental
Determinants of Diabetes in the Young
(TEDDY) multinational study began en-
rolling newborns with HLA-conferred
type 1 diabetes susceptibility both from
the general population of newborns and
from newborns with affected ﬁrst-degree
relatives (6). The TEDDY study has now
completed screening with nearly 8,000
infants enrolled.
Almost without exception, the ongo-
ing early type 1 diabetes prediction and
prevention studies recruit subjects at
birth or within the ﬁrst few months of life
and aim to follow the children until at
least 10 to 15 years of age. Due to the
highly variable incidence numbers in dif-
ferent European and U.S. populations,
the cost-efﬁciency of the recruitment
strategy may differ markedly in different
corners of the world. To optimize the
strategy for the long-term assessment of
type 1 diabetes risk, the information ob-
tained in the birth-onset studies must to
be connected to, and correlated with, in-
formation obtained by following the co-
horts through the years of puberty and
early adulthood. The data from the stud-
ies with enrollment at birth strongly
suggest that early seroconversion to auto-
antibody positivity provides a high risk
for progressing to clinical type 1 diabetes
at a young age, but clearly, some excep-
tionsexist.Althoughpositivityforasin-
gle autoantibody often indicates only
minor or no increase in risk, the risk
may by high if samples are collected at
frequent intervals in which seroconver-
sion to two or more autoantibodies
occurs over time. As none of the predic-
tion-oriented studies with onset at birth
has continued long enough for a large
cohort to reach puberty and young
adulthood, little is known of the predic-
tive characteristics and fate of the auto-
antibodies in this age-group.
To date only a few long-term popula-
tion–based studies have primarily tested
thepredictiveabilityofautoantibodypos-
itivity in the general population (7–10).
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(11) have utilized serum samples col-
lected 6 years apart in the Cardiovascular
Risk in Young Finns (LASERI) study. The
authors have sought to test the predictive
abilityofGADAandIA-2Ameasurements
in the general population by examining
thedevelopmentofclinicaldiabetesinthe
cohort for up to 27 years. As part of their
study, they evaluated the 6-year rates of
seroconversion to GADA and IA-2A pos-
itivity and whether these autoantibodies
persist or disappear during follow-up.
The ﬁrst samples were collected in 1980
from a general population cohort com-
prising 3,500 children ages 3, 6, 9, 12,
15, and 18 years. In 1986, new samples
were obtained from 2,400 of the chil-
dren tested in 1980 whose ages then
ranged from 9 to 24 years. GADA and
IA-2Aweremeasuredinalltheavailable
samples and, if positive for either one of
these two autoantibodies, the two sam-
ples from that individual were then
testedforICAandIAA.Theendpointof
the study was progression to clinical
type 1 diabetes by the end of the year
2007.
Although the absolute number of
childrenwhohadseroconvertedtoGADA
or IA-2A positivity before 1980 were un-
derstandably low (34 for GADA and 22
for IA-2A), and the number of children
who seroconverted to GADA or IA-2A
positivityduringthefollowing6years(by
the year 1986) were even lower (9 and 4,
respectively), the data supported the con-
clusion that a one-time screening for
GADA and IA-2A in the general child-
hood population in Finland would iden-
tify 60% of those who would develop
type1diabetesoverthenext27years,and
those individuals who had both autoanti-
bodies were at an extremely high risk for
type 1 diabetes. The authors also deter-
mined that autoantibodies continue to
both emerge and disappear during and
after puberty. However, the autoantibod-
ies disappear predominantly from sub-
jects who are positive for only one
autoantibody.
Unfortunately, since the risk in the
general population is low, even a small
false-positive rate will identify many sub-
jects who will never develop the disease
(Bayes Theorem). Screening with and
ﬁnding two or more antibodies increases
the positive predictive value but reduces
sensitivity and markedly increases cost.
This notion is supported by Knip et al. in
their study, which also followed patients
over a longer period of time as compared
withpreviousstudies.Thecombinedsen-
sitivity of 61% for GADA and/or IA-2A in
the prediction of type 1 diabetes demon-
strates that other markers of islet autoim-
munity may be important (e.g., ICA,
ZnT8A, and in children, IAA). In clinical
practice if one were to seek markers used
to predict type 1 diabetes, GADA and
IA-2A testing alone would have an unac-
ceptably low sensitivity.
Although the study provides valuable
information, some questions remain.
Most subjects who developed autoanti-
bodies or were autoantibody positive in
the 1980 or 1986 blood draw were pre-
pubertal or pubertal. Any events occur-
ringbefore3yearsofageareunknown.In
contrast,since18yearswastheupperage
recruited, there are no data about sero-
conversion in older subjects. It is not
known in patients with LADA or adult
type 1 diabetes whether the appearance
of autoantibodies may occur later. An-
other drawback in this study is the ab-
senceofgeneticinformationconcerning
the study subjects. Hopefully such data
and an analysis of type 1 diabetes–
related risk factors will be made avail-
able soon. As the cohort grows older, it
will be interesting to follow the appear-
ance and disappearance of autoantibod-
ies and the progression to disease.
Despite emerging technologies such as
metabolomics, gene expression proﬁl-
ing, and pathway analyses (12), autoan-
tibodies will most likely remain one of
the most broadly utilized predictors of
type 1 diabetes.
The greatest single barrier toward
wide-scale population screening and pre-
vention of the disease is the hitherto lack
of an effective intervention. It is clear that
screening for type 1 diabetes risk in the
general population still should only be
conducted in the context of deﬁned re-
search questions.
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